Mechanism and treatment associated with resistance to EGFR-TKI / 国际肿瘤学杂志

ABSTRACT

Epidermal growth factor receptor tyrosine kinases inhibitor (EGFR-TKI) has impressive clinical efficacy in EGFR-mutant non-small cell lung cancer. However,there are still some patients with primary resistance to TKI.And most patients who initially respond to treatment eventually develop resistance to these drugs,which the main molecular mechanisms are T790M and MET amplification.The new targeted therapies and combination drugs to overcome drug resistance is the subject of clinical research.